WASHINGTON, DC (GenomeWeb News) – Australian molecular diagnostics developer Proteome Systems has closed a private placement of AUD$2.5 million (US$2.2 million), the company said today.
 
Proteome Systems will issue 23,809,524 shares at AUD$0.105 per share to participants in the funding including Oppenheimer Funds and other US and Australian investors.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.